Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis

Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis

Marks start of European commercial rollout of aXess™, bringing it into routine clinical practiceBuilds on CE mark

Trial of restorative vascular access conduit reaches 50% enrolment

Axess graft Xeltis has announced that it has exceeded 50% enrolment in its US pivotal trial for aXess, its restorative vascular access conduit for haemodialysis treatment. The US pivotal trial is a prospective, multicentre study evaluating the patency, safety, and performance of aXess in adult patients with end-stage renal disease (ESRD) requiring vascular access for haemodialysis. To date, over 50% of the target patient enrolment has been achie…